Bone and Mineral Metabolism Disorders News

For patients with kidney disease, calcimimetic agents lowered parathyroid hormone levels in the short term, with each agent consisting of a different side-effect profile, according to a systematic study review.

Long-term use of unfractionated heparin may be associated with the loss of lumbar spine bone mineral density in patients undergoing maintenance hemodialysis treatment, according to a published study.

The trajectories of serum sodium levels in hospitalized patients may help predict in-hospital mortality and mortality risk at 1 year, with the highest risk of death found when serum sodium fluctuated “considerably,” according to this study.

The FDA has updated the dosing regimen for Lokelma to allow treatment of hyperkalemia in patients with end-stage kidney disease who are on chronic hemodialysis.

A study involving participants from Australia, Hong Kong, the United Kingdom and the United States, revealed what is most important to patients with glomerular disease and their caregivers. The highest-rated priorities were related to kidney health and survival, as well to the ability to actively participate in their lives and the impact on family members.

Sucroferric oxyhydroxide treatment in patients on hemodialysis resulted in improved serum phosphorus control, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.

Parathyroidectomies in secondary hyperparathyroidism result in significantly higher costs and higher rates of morbidity, mortality and complications compared to primary hyperparathyroidism, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.

Data from Fresenius Medical Care North America-directed ESRD Seamless Care Organizations show the type of phosphate binder used by clinics during the demonstration influenced hospital admissions and overall cost of care, according to an abstract at the virtual National Kidney Foundation Spring Clinical Meetings.

For patients with chronic kidney disease and diabetes, veverimer appeared to be an effective treatment for metabolic acidosis, as it improved both quality of life and physical function, according to phase 3 trial results. The results were presented virtually at the National Kidney Foundation Spring Clinical Meetings.

Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased serum phosphorous in patients with chronic kidney disease on dialysis, according to a press release from Ardelyx Inc.